Literature DB >> 31624067

Head and Neck Cancers Promote an Inflammatory Transcriptome through Coactivation of Classic and Alternative NF-κB Pathways.

Xinping Yang1, Hui Cheng1, Jianhong Chen1, Ru Wang1,2, Anthony Saleh1, Han Si1, Steven Lee1, Emine Guven-Maiorov3,4, Ozlem Keskin4,5, Attila Gursoy6,5, Ruth Nussinov3, Jugao Fang2, Carter Van Waes7, Zhong Chen7.   

Abstract

Head and neck squamous cell carcinomas (HNSCC) promote inflammation in the tumor microenvironment through aberrant NF-κB activation, but the genomic alterations and pathway networks that modulate NF-κB signaling have not been fully dissected. Here, we analyzed genome and transcriptome alterations of 279 HNSCC specimens from The Cancer Genome Atlas (TCGA) cohort and identified 61 genes involved in NF-κB and inflammatory pathways. The top 30 altered genes were distributed across 96% of HNSCC samples, and their expression was often correlated with genomic copy-number alterations (CNA). Ten of the amplified genes were associated with human papilloma virus (HPV) status. We sequenced 15 HPV- and 11 HPV+ human HNSCC cell lines, and three oral mucosa keratinocyte lines, and supervised clustering revealed that 28 of 61 genes exhibit altered expression patterns concordant with HNSCC tissues and distinct signatures related to their HPV status. RNAi screening using an NF-κB reporter line identified 16 genes that are induced by TNFα or Lymphotoxin-β (LTβ) and implicated in the classic and/or alternative NF-κB pathways. Knockdown of TNFR, LTBR, or selected downstream signaling components established cross-talk between the classic and alternative NF-κB pathways. TNFα and LTβ induced differential gene expression involving the NF-κB, IFNγ, and STAT pathways, inflammatory cytokines, and metastasis-related genes. Improved survival was observed in HNSCC patients with elevated gene expression in T-cell activation, immune checkpoints, and IFNγ and STAT pathways. These gene signatures of NF-κB activation, which modulate inflammation and responses to the immune therapy, could serve as potential biomarkers in future clinical trials. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31624067      PMCID: PMC6941750          DOI: 10.1158/2326-6066.CIR-18-0832

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  54 in total

Review 1.  HPV-associated head and neck cancer: a virus-related cancer epidemic.

Authors:  Shanthi Marur; Gypsyamber D'Souza; William H Westra; Arlene A Forastiere
Journal:  Lancet Oncol       Date:  2010-05-05       Impact factor: 41.316

Review 2.  Immunity, inflammation, and cancer.

Authors:  Sergei I Grivennikov; Florian R Greten; Michael Karin
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

3.  Dual Antagonist of cIAP/XIAP ASTX660 Sensitizes HPV- and HPV+ Head and Neck Cancers to TNFα, TRAIL, and Radiation Therapy.

Authors:  Roy Xiao; Yi An; Wenda Ye; Adeeb Derakhshan; Hui Cheng; Xinping Yang; Clint Allen; Zhong Chen; Nicole C Schmitt; Carter Van Waes
Journal:  Clin Cancer Res       Date:  2019-07-02       Impact factor: 12.531

4.  Inhibitor-kappaB kinase in tumor promotion and suppression during progression of squamous cell carcinoma.

Authors:  Carter Van Waes; Ming Yu; Liesl Nottingham; Michael Karin
Journal:  Clin Cancer Res       Date:  2007-09-01       Impact factor: 12.531

5.  Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade.

Authors:  Pornpimol Charoentong; Francesca Finotello; Mihaela Angelova; Clemens Mayer; Mirjana Efremova; Dietmar Rieder; Hubert Hackl; Zlatko Trajanoski
Journal:  Cell Rep       Date:  2017-01-03       Impact factor: 9.423

6.  The prognostic landscape of genes and infiltrating immune cells across human cancers.

Authors:  Andrew J Gentles; Aaron M Newman; Chih Long Liu; Scott V Bratman; Weiguo Feng; Dongkyoon Kim; Viswam S Nair; Yue Xu; Amanda Khuong; Chuong D Hoang; Maximilian Diehn; Robert B West; Sylvia K Plevritis; Ash A Alizadeh
Journal:  Nat Med       Date:  2015-07-20       Impact factor: 53.440

7.  Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade.

Authors:  Joseph L Benci; Bihui Xu; Yu Qiu; Tony J Wu; Hannah Dada; Christina Twyman-Saint Victor; Lisa Cucolo; David S M Lee; Kristen E Pauken; Alexander C Huang; Tara C Gangadhar; Ravi K Amaravadi; Lynn M Schuchter; Michael D Feldman; Hemant Ishwaran; Robert H Vonderheide; Amit Maity; E John Wherry; Andy J Minn
Journal:  Cell       Date:  2016-12-01       Impact factor: 41.582

8.  Lymphotoxin-β receptor-NIK signaling induces alternative RELB/NF-κB2 activation to promote metastatic gene expression and cell migration in head and neck cancer.

Authors:  Rita Das; Jamie Coupar; Paul E Clavijo; Anthony Saleh; Tsu-Fan Cheng; Xinping Yang; Jianhong Chen; Carter Van Waes; Zhong Chen
Journal:  Mol Carcinog       Date:  2018-11-28       Impact factor: 4.784

9.  PRISM: protein interactions by structural matching.

Authors:  Utkan Ogmen; Ozlem Keskin; A Selim Aytuna; Ruth Nussinov; Attila Gursoy
Journal:  Nucleic Acids Res       Date:  2005-07-01       Impact factor: 16.971

10.  Aberrant IKKα and IKKβ cooperatively activate NF-κB and induce EGFR/AP1 signaling to promote survival and migration of head and neck cancer.

Authors:  L K Nottingham; C H Yan; X Yang; H Si; J Coupar; Y Bian; T-F Cheng; C Allen; P Arun; D Gius; L Dang; C Van Waes; Z Chen
Journal:  Oncogene       Date:  2013-03-04       Impact factor: 9.867

View more
  9 in total

Review 1.  Evodiamine as an anticancer agent: a comprehensive review on its therapeutic application, pharmacokinetic, toxicity, and metabolism in various cancers.

Authors:  Munmun Panda; Surya Kant Tripathi; Gokhan Zengin; Bijesh K Biswal
Journal:  Cell Biol Toxicol       Date:  2022-09-23       Impact factor: 6.819

2.  Identification of a novel ceRNA network related to prognosis and immunity in HNSCC based on integrated bioinformatic investigation.

Authors:  Hongbo Liu; Guoli Hei; Lu Zhang; Yanxia Jiang; Haijun Lu
Journal:  Sci Rep       Date:  2022-10-20       Impact factor: 4.996

Review 3.  Enhanced Radiation Sensitivity of Human Papillomavirus-Driven Head and Neck Cancer: Focus on Immunological Aspects.

Authors:  Mine Özcan-Wahlbrink; Christoph Schifflers; Angelika B Riemer
Journal:  Front Immunol       Date:  2019-12-03       Impact factor: 7.561

Review 4.  Signaling pathways of EBV-induced oncogenesis.

Authors:  Yin Luo; Yitong Liu; Chengkun Wang; Runliang Gan
Journal:  Cancer Cell Int       Date:  2021-02-06       Impact factor: 5.722

Review 5.  Human Papillomavirus Infection in Head and Neck Squamous Cell Carcinomas: Transcriptional Triggers and Changed Disease Patterns.

Authors:  Nikita Aggarwal; Joni Yadav; Kulbhushan Thakur; Rakhi Bibban; Arun Chhokar; Tanya Tripathi; Anjali Bhat; Tejveer Singh; Mohit Jadli; Ujala Singh; Manoj K Kashyap; Alok C Bharti
Journal:  Front Cell Infect Microbiol       Date:  2020-12-02       Impact factor: 5.293

6.  Cancer-specific type-I interferon receptor signaling promotes cancer stemness and effector CD8+ T-cell exhaustion.

Authors:  Wang Gong; Christopher R Donnelly; Blake R Heath; Emily Bellile; Lorenza A Donnelly; Hülya F Taner; Luke Broses; J Chad Brenner; Steven B Chinn; Ru-Rong Ji; Haitao Wen; Jacques E Nör; Jie Wang; Gregory T Wolf; Yuying Xie; Yu Leo Lei
Journal:  Oncoimmunology       Date:  2021-11-13       Impact factor: 7.723

7.  CX-4945 and siRNA-Mediated Knockdown of CK2 Improves Cisplatin Response in HPV(+) and HPV(-) HNSCC Cell Lines.

Authors:  Janeen H Trembley; Bin Li; Betsy T Kren; Amy A Gravely; Emiro Caicedo-Granados; Mark A Klein; Khalil Ahmed
Journal:  Biomedicines       Date:  2021-05-18

Review 8.  IL-1/IL-1R Signaling in Head and Neck Cancer.

Authors:  Sven E Niklander; Craig Murdoch; Keith D Hunter
Journal:  Front Oral Health       Date:  2021-08-26

Review 9.  Inflammatory Mediators in Oral Cancer: Pathogenic Mechanisms and Diagnostic Potential.

Authors:  Sven E Niklander
Journal:  Front Oral Health       Date:  2021-02-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.